Human Peripheral Blood Macrophages As a Model for Studying Glucocerebrosidase Dysfunction


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Только для подписчиков

Аннотация

Decreased activity of glucocerebrosidase (GCase) as a result of mutations in the GBA gene causes Gaucher’s disease (GD), which belongs to the group of lysosomal storage disorders. The risk of Parkinson’s disease in homo- and heterozygous carriers of GBA mutations is elevated seven- to eightfold. Screening of novel compounds designed to enhance GCase activity requires development of in vitro models based on primary cell cultures obtained from patients carrying GBA mutations. In this work, the efficiency of different methods used to culture peripheral blood macrophages of GD patients and control subjects was compared, and GCase activity and lysosphingolipid concentrations were evaluated using tandem mass spectrometry (HPLC‒MS/MS) in dried cell spots. For the first time, the efficacy of restoring the activity of mutant GCase has been assessed in primary macrophages of GD patients cultured in the presence of pharmacological GCase chaperones isofagomine and ambroxol. Based on these results, a convenient method of in vitro screening of candidate pharmacological agents designed to increase GCase activity can be proposed.

Об авторах

M. Nikolaev

St. Petersburg Konstantinov Institute of Nuclear Physics, National Research Center Kurchatov Institute; Pavlov First St. Petersburg State Medical University

Автор, ответственный за переписку.
Email: Nikolaev_MA@pnpi.nrcki.ru
Россия, Gatchina, Leningrad oblast, 188300; St. Petersburg, 197022

A. Kopytova

St. Petersburg Konstantinov Institute of Nuclear Physics, National Research Center Kurchatov Institute

Email: Nikolaev_MA@pnpi.nrcki.ru
Россия, Gatchina, Leningrad oblast, 188300

G. Baidakova

Research Center of Medical Genetics

Email: Nikolaev_MA@pnpi.nrcki.ru
Россия, Moscow, 115522

A. Emel’yanov

St. Petersburg Konstantinov Institute of Nuclear Physics, National Research Center Kurchatov Institute; Pavlov First St. Petersburg State Medical University

Email: Nikolaev_MA@pnpi.nrcki.ru
Россия, Gatchina, Leningrad oblast, 188300; St. Petersburg, 197022

G. Salogub

Almazov National Medical Research Center, Ministry of Health of the Russian Federation

Email: Nikolaev_MA@pnpi.nrcki.ru
Россия, St. Petersburg, 197341

K. Senkevich

St. Petersburg Konstantinov Institute of Nuclear Physics, National Research Center Kurchatov Institute; Pavlov First St. Petersburg State Medical University

Email: Nikolaev_MA@pnpi.nrcki.ru
Россия, Gatchina, Leningrad oblast, 188300; St. Petersburg, 197022

T. Usenko

St. Petersburg Konstantinov Institute of Nuclear Physics, National Research Center Kurchatov Institute; Pavlov First St. Petersburg State Medical University

Email: Nikolaev_MA@pnpi.nrcki.ru
Россия, Gatchina, Leningrad oblast, 188300; St. Petersburg, 197022

M. Gorchakova

Pavlov First St. Petersburg State Medical University

Email: Nikolaev_MA@pnpi.nrcki.ru
Россия, St. Petersburg, 197022

Yu. Koval’chuk

Pavlov First St. Petersburg State Medical University

Email: Nikolaev_MA@pnpi.nrcki.ru
Россия, St. Petersburg, 197022

O. Berkovich

Pavlov First St. Petersburg State Medical University

Email: Nikolaev_MA@pnpi.nrcki.ru
Россия, St. Petersburg, 197022

E. Zakharova

Research Center of Medical Genetics

Email: Nikolaev_MA@pnpi.nrcki.ru
Россия, Moscow, 115522

S. Pchelina

St. Petersburg Konstantinov Institute of Nuclear Physics, National Research Center Kurchatov Institute; Pavlov First St. Petersburg State Medical University

Email: Nikolaev_MA@pnpi.nrcki.ru
Россия, Gatchina, Leningrad oblast, 188300; St. Petersburg, 197022


© Pleiades Publishing, Ltd., 2019

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах